S&P 500   4,565.43 (+0.23%)
DOW   35,547.03 (+0.37%)
QQQ   390.93 (+0.19%)
AAPL   189.48 (-0.48%)
MSFT   378.78 (-1.02%)
META   333.51 (-1.62%)
GOOGL   135.53 (-1.22%)
AMZN   146.57 (-0.31%)
TSLA   246.84 (+0.05%)
NVDA   480.96 (+0.58%)
NIO   7.24 (+0.42%)
BABA   74.86 (-2.45%)
AMD   124.39 (+1.95%)
T   16.26 (+0.49%)
F   10.63 (+2.51%)
MU   76.92 (+1.05%)
CGC   0.57 (+4.96%)
GE   119.02 (+0.14%)
DIS   92.82 (+0.35%)
AMC   7.18 (+7.16%)
PFE   30.06 (+1.25%)
PYPL   58.68 (+0.36%)
XOM   103.57 (-0.32%)
S&P 500   4,565.43 (+0.23%)
DOW   35,547.03 (+0.37%)
QQQ   390.93 (+0.19%)
AAPL   189.48 (-0.48%)
MSFT   378.78 (-1.02%)
META   333.51 (-1.62%)
GOOGL   135.53 (-1.22%)
AMZN   146.57 (-0.31%)
TSLA   246.84 (+0.05%)
NVDA   480.96 (+0.58%)
NIO   7.24 (+0.42%)
BABA   74.86 (-2.45%)
AMD   124.39 (+1.95%)
T   16.26 (+0.49%)
F   10.63 (+2.51%)
MU   76.92 (+1.05%)
CGC   0.57 (+4.96%)
GE   119.02 (+0.14%)
DIS   92.82 (+0.35%)
AMC   7.18 (+7.16%)
PFE   30.06 (+1.25%)
PYPL   58.68 (+0.36%)
XOM   103.57 (-0.32%)
S&P 500   4,565.43 (+0.23%)
DOW   35,547.03 (+0.37%)
QQQ   390.93 (+0.19%)
AAPL   189.48 (-0.48%)
MSFT   378.78 (-1.02%)
META   333.51 (-1.62%)
GOOGL   135.53 (-1.22%)
AMZN   146.57 (-0.31%)
TSLA   246.84 (+0.05%)
NVDA   480.96 (+0.58%)
NIO   7.24 (+0.42%)
BABA   74.86 (-2.45%)
AMD   124.39 (+1.95%)
T   16.26 (+0.49%)
F   10.63 (+2.51%)
MU   76.92 (+1.05%)
CGC   0.57 (+4.96%)
GE   119.02 (+0.14%)
DIS   92.82 (+0.35%)
AMC   7.18 (+7.16%)
PFE   30.06 (+1.25%)
PYPL   58.68 (+0.36%)
XOM   103.57 (-0.32%)
S&P 500   4,565.43 (+0.23%)
DOW   35,547.03 (+0.37%)
QQQ   390.93 (+0.19%)
AAPL   189.48 (-0.48%)
MSFT   378.78 (-1.02%)
META   333.51 (-1.62%)
GOOGL   135.53 (-1.22%)
AMZN   146.57 (-0.31%)
TSLA   246.84 (+0.05%)
NVDA   480.96 (+0.58%)
NIO   7.24 (+0.42%)
BABA   74.86 (-2.45%)
AMD   124.39 (+1.95%)
T   16.26 (+0.49%)
F   10.63 (+2.51%)
MU   76.92 (+1.05%)
CGC   0.57 (+4.96%)
GE   119.02 (+0.14%)
DIS   92.82 (+0.35%)
AMC   7.18 (+7.16%)
PFE   30.06 (+1.25%)
PYPL   58.68 (+0.36%)
XOM   103.57 (-0.32%)

United Therapeutics Stock Price, News & Analysis (NASDAQ:UTHR)

$230.45
+0.06 (+0.03%)
(As of 01:14 PM ET)
Compare
Today's Range
$230.45
$234.03
50-Day Range
$219.23
$236.77
52-Week Range
$204.44
$283.09
Volume
87,587 shs
Average Volume
392,162 shs
Market Capitalization
$10.83 billion
P/E Ratio
12.70
Dividend Yield
N/A
Price Target
$288.00

United Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
25.0% Upside
$288.00 Price Target
Short Interest
Bearish
2.40% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.00
Upright™ Environmental Score
News Sentiment
0.88mentions of United Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$6.81 M Sold Last Quarter
Proj. Earnings Growth
12.81%
From $19.44 to $21.93 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.53 out of 5 stars

Medical Sector

53rd out of 949 stocks

Pharmaceutical Preparations Industry

19th out of 437 stocks


UTHR stock logo

About United Therapeutics Stock (NASDAQ:UTHR)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and TETON studies, which are the studies of Tyvaso for the treatment of idiopathic pulmonary fibrosis. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

UTHR Stock Price History

UTHR Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Jim Simons Stock Portfolio: 12 Biggest Healthcare Stocks
3d Systems (DDD) Q3 2023 Earnings Call Transcript
The Only Practical Solution to the World’s Looming Energy Crisis
There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!
Q3 2023 United Therapeutics Corp Earnings Call
United Therapeutics to Acquire Miromatrix Medical
See More Headlines
Receive UTHR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2023
Today
11/29/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/28/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:UTHR
CUSIP
91307C10
Employees
985
Year Founded
1996

Price Target and Rating

Average Stock Price Target
$288.00
High Stock Price Target
$314.00
Low Stock Price Target
$230.00
Potential Upside/Downside
+25.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
8 Analysts

Profitability

Net Income
$727.30 million
Pretax Margin
52.52%

Debt

Sales & Book Value

Annual Sales
$1.94 billion
Cash Flow
$17.03 per share
Book Value
$105.24 per share

Miscellaneous

Free Float
41,120,000
Market Cap
$10.83 billion
Optionable
Optionable
Beta
0.57

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives















UTHR Stock Analysis - Frequently Asked Questions

Should I buy or sell United Therapeutics stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 1 sell rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" UTHR shares.
View UTHR analyst ratings
or view top-rated stocks.

What is United Therapeutics' stock price target for 2024?

8 Wall Street research analysts have issued 1 year price targets for United Therapeutics' stock. Their UTHR share price targets range from $230.00 to $314.00. On average, they anticipate the company's share price to reach $288.00 in the next year. This suggests a possible upside of 24.5% from the stock's current price.
View analysts price targets for UTHR
or view top-rated stocks among Wall Street analysts.

How have UTHR shares performed in 2023?

United Therapeutics' stock was trading at $278.09 at the beginning of the year. Since then, UTHR shares have decreased by 16.8% and is now trading at $231.32.
View the best growth stocks for 2023 here
.

When is United Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024.
View our UTHR earnings forecast
.

How were United Therapeutics' earnings last quarter?

United Therapeutics Co. (NASDAQ:UTHR) released its earnings results on Wednesday, November, 1st. The biotechnology company reported $5.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.10 by $0.28. The biotechnology company had revenue of $609.40 million for the quarter, compared to the consensus estimate of $585.82 million. United Therapeutics had a trailing twelve-month return on equity of 17.10% and a net margin of 40.82%. The company's revenue was up 18.1% compared to the same quarter last year. During the same period in the previous year, the company posted $4.91 earnings per share.

What is Martine A. Rothblatt's approval rating as United Therapeutics' CEO?

64 employees have rated United Therapeutics Chief Executive Officer Martine A. Rothblatt on Glassdoor.com. Martine A. Rothblatt has an approval rating of 88% among the company's employees.

What other stocks do shareholders of United Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), General Electric (GE), Johnson & Johnson (JNJ), Skyworks Solutions (SWKS), Allergan (AGN) and Pfizer (PFE).

Who are United Therapeutics' major shareholders?

United Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (5.54%), Palo Alto Investors LP (1.23%), Bank of New York Mellon Corp (1.22%), AQR Capital Management LLC (1.01%), Fuller & Thaler Asset Management Inc. (0.92%) and Northern Trust Corp (0.83%). Insiders that own company stock include Christopher Causey, Christopher Patusky, Judy D Olian, Louis W Sullivan, Martine A Rothblatt, Nilda Mesa, Paul A Mahon, Paul A Mahon and Raymond Dwek.
View institutional ownership trends
.

How do I buy shares of United Therapeutics?

Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:UTHR) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -